Matthias Guckenberger1, Nicolaus Andratschke2, Karin Dieckmann3, Mischa S Hoogeman4, Morten Hoyer5, Coen Hurkmans6, Stephanie Tanadini-Lang2, Eric Lartigau7, Alejandra Méndez Romero4, Suresh Senan8, Dirk Verellen9. 1. Department of Radiation Oncology, University Hospital Zürich, Switzerland. Electronic address: matthias.guckenberger@usz.ch. 2. Department of Radiation Oncology, University Hospital Zürich, Switzerland. 3. Department of Radiation Oncology, Medical University of Vienna, Austria. 4. Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 5. Department of Radiation Oncology, Aarhus University Hospital, Denmark. 6. Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands. 7. Department of Radiation Oncology, Centre Oscar Lambret, Lille, France. 8. Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands. 9. Department of Radiation Oncology, UZ Brussel (VUB), Belgium.
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) has become the standard of care for medically inoperable patients with peripherally located, early stage non-small cell lung cancer (NSCLC), and for those refusing surgical resection. Despite the availability of national and international guidelines, there exists substantial variability in many aspects of SBRT practice. METHODS: The ESTRO ACROP guideline is based on a questionnaire covering all aspects of SBRT implementation and practice (n=114 items). The questionnaire was answered by the 11 faculty members of the ESTRO course "Clinical practice and implementation of image-guided SBRT" and their 8 institutions. RESULTS: Agreement by >50% of the institutions was achieved in 72% of all items. Only 8/57 technologies and techniques were identified as mandatory for SBRT while 32/57 were considered as optional. In contrast, quality-assurance related elements were considered as mandatory in 12/24 items. A consensus of risk-adapted SBRT fractionation was achieved with 3×15Gy for peripherally located lesions and 4×12Gy (PTV D95-D99; Dmax <125% to <150%) for lesions with broad chest wall contact. For patients free from severe comorbidities and with favourable long-term OS expectancy, use of the maximum tolerated dose of 3×18Gy should be considered. CONCLUSIONS: This ACROP guideline achieved detailed recommendations in all aspects of SBRT implementation and practice, which will contribute to further standardization of SBRT for peripherally located early stage NSCLC.
BACKGROUND: Stereotactic body radiotherapy (SBRT) has become the standard of care for medically inoperable patients with peripherally located, early stage non-small cell lung cancer (NSCLC), and for those refusing surgical resection. Despite the availability of national and international guidelines, there exists substantial variability in many aspects of SBRT practice. METHODS: The ESTRO ACROP guideline is based on a questionnaire covering all aspects of SBRT implementation and practice (n=114 items). The questionnaire was answered by the 11 faculty members of the ESTRO course "Clinical practice and implementation of image-guided SBRT" and their 8 institutions. RESULTS: Agreement by >50% of the institutions was achieved in 72% of all items. Only 8/57 technologies and techniques were identified as mandatory for SBRT while 32/57 were considered as optional. In contrast, quality-assurance related elements were considered as mandatory in 12/24 items. A consensus of risk-adapted SBRT fractionation was achieved with 3×15Gy for peripherally located lesions and 4×12Gy (PTV D95-D99; Dmax <125% to <150%) for lesions with broad chest wall contact. For patients free from severe comorbidities and with favourable long-term OS expectancy, use of the maximum tolerated dose of 3×18Gy should be considered. CONCLUSIONS: This ACROP guideline achieved detailed recommendations in all aspects of SBRT implementation and practice, which will contribute to further standardization of SBRT for peripherally located early stage NSCLC.
Authors: Lotte Wilke; Nicolaus Andratschke; Oliver Blanck; Thomas B Brunner; Stephanie E Combs; Anca-Ligia Grosu; Christos Moustakis; Daniela Schmitt; Wolfgang W Baus; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2019-01-16 Impact factor: 3.621
Authors: Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Eich; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2017-09-15 Impact factor: 3.621
Authors: Gabriella Macchia; Roberta Lazzari; Nicoletta Colombo; Concetta Laliscia; Giovanni Capelli; Giuseppe Roberto D'Agostino; Francesco Deodato; Ernesto Maranzano; Edy Ippolito; Sara Ronchi; Fabiola Paiar; Marta Scorsetti; Savino Cilla; Rossana Ingargiola; Alessandra Huscher; Anna Maria Cerrotta; Andrei Fodor; Lisa Vicenzi; Donatella Russo; Simona Borghesi; Elisabetta Perrucci; Sandro Pignata; Cynthia Aristei; Alessio Giuseppe Morganti; Giovanni Scambia; Vincenzo Valentini; Barbara Alicja Jereczek-Fossa; Gabriella Ferrandina Journal: Oncologist Date: 2019-10-10
Authors: Matthew Beasley; Sean Brown; Helen McNair; Corinne Faivre-Finn; Kevin Franks; Louise Murray; Marcel van Herk; Ann Henry Journal: Br J Radiol Date: 2019-04-24 Impact factor: 3.039